Technology Profiles
 Profile Detail
Novel targeted autoimmunization for the prevention of HIV Infection (10 GB 44O7 3GCI)
A UK London-based organisation has developed a novel immunopeptide that generates a sustained antibody response that inhibits HIV infection, without causing an autoimmune response. Their composition describes a biopharmaceutical technology that inhibits HIV cell entry via blocking of CCR5. Based on the success of the pre-clinical data a partner is sought for possible collaboration in the next phase of study.
Country: United Kingdom
Type: OFFER
Date: 25.10.2010
Current vaccines against HIV do not work, largely because the virus is extremely variable. An alternative approach is to block viral entry, by targeting the human receptor (CCR5) which is essential for the first steps of infection.
Targeting self receptors can be difficult, because the immune response tries to avoid reacting against "self". It can also be hazardous, since the autoimmune response can damage the host.
This novel immunopeptide generates a sustained antibody response that inhibits HIV infection, without causing an autoimmune response.
Innovative Aspects:
It is well known in the field that the inhibition of CCR5 is a viable strategy for impeding HIV infection. This technology generates an antibody response to one selected section of the CCR5 receptor, but induces no cellular immune response to the protein. Data to date indicates that functional antibodies are generated, and bind to the CCR5 protein.
Degree of development:
Patents/Rights: Patent(s) applied for but not yet granted
Requested Cooperation: License Agreement, Joint further development
- Type of partner sought: Industry
- Specific area of activity of the partner: Therapies
- Task to be performed by the partner sought: Development in next phase of study
Type of Organisation:
Status: NEW
| 
